Daunorubicin
- Generic Name
- Daunorubicin
- Brand Names
- Cerubidine, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO10
- CAS Number
- 20830-81-3
- Unique Ingredient Identifier
- ZS7284E0ZP
- Background
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms.
- Indication
For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.
...
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Chronic Phase Chronic Myeloid Leukemia, Ewing's Sarcoma, Lymphoma, Diffuse, Myeloblastic Leukemia, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Wilms' tumor
- Associated Therapies
- -
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
- Conditions
- Interventions
- First Posted Date
- 2008-11-11
- Last Posted Date
- 2018-01-12
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 126
- Registration Number
- NCT00788892
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸North Shore University Hospital, Manhasset, New York, United States
🇺🇸Arizona Cancer Center, Tucson, Arizona, United States
Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2008-06-24
- Last Posted Date
- 2021-08-10
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 324
- Registration Number
- NCT00703820
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Stanford University Medical Center, Palo Alto, California, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2021-08-18
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 717
- Registration Number
- NCT00651261
- Locations
- 🇺🇸
St. Luke's Regional Medical Center, Sioux City, Iowa, United States
🇺🇸Ministry Saint Clare's Hospital, Weston, Wisconsin, United States
🇺🇸Cancer Centers of the Carolinas - Easley, Easley, South Carolina, United States
Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2015-01-14
- Target Recruit Count
- 2039
- Registration Number
- NCT00613457
DaunoXome + Ara-C vs Daunorubicin + Ara-C in Elderly AML
LAL-BR/2001: Study Treatment to Low Risk ALL
- Conditions
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2016-01-20
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 150
- Registration Number
- NCT00526175
- Locations
- 🇪🇸
Basurtuko Ospitalea, Basurto, Spain
🇪🇸Complejo Hospitalario Universitario de Albacete, Albacete, Spain
🇪🇸Hospital General de Alicante, Alicante, Spain
LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 40
- Registration Number
- NCT00526409
- Locations
- 🇪🇸
Hospital Niño Jesús, Madrid, Spain
🇪🇸Hospital materno Infantil vall d'Hebrón, Barcelona, Spain
🇪🇸Hospital Infantil Carlos Haya, Málaga, Spain
LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive
- Conditions
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2010-01-05
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 100
- Registration Number
- NCT00526305
- Locations
- 🇪🇸
Hospital General de Segovia, Segovia, Spain
🇪🇸Hospital Universitario de Canarias, Tenerife, Spain
🇪🇸H.U. Virgen del Rocio, Sevilla, Spain
PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2007-07-02
- Last Posted Date
- 2009-05-19
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 374
- Registration Number
- NCT00494897
- Locations
- 🇪🇸
Hospital Central de Asturias, Oviedo, Asturias, Spain
🇪🇸Hospital general de Castellón, Castello, Castellón, Spain
🇪🇸Hospital Mútua de Terrassa, Terrassa, Barcelona, Spain
AML Treatment in Untreated Adult Patients
- Conditions
- Locations
- 🇮🇹
Dr.ssa Mastrullo, Napoli, Italy
🇮🇹Prof. D'Arco, Nocera Inferiore, Italy
🇮🇹Prof. Saglio, Orbassano, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.